<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118179</url>
  </required_header>
  <id_info>
    <org_study_id>H17-01208</org_study_id>
    <nct_id>NCT04118179</nct_id>
  </id_info>
  <brief_title>New Strategy to Predict Early Sepsis</brief_title>
  <official_title>Development of a New Strategy to Predict Early Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective multicentre study on patients attending the emergency
      department and suspected to have sepsis. Blood markers characteristic of a Cellular
      Reprogramming (CR) signature and predicting severe sepsis and organ failure will be measured
      and validated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is a life-threatening medical condition caused by an infection and the complex and
      dysfunctional way by which the human body attempts to deal with it. It can affect people of
      all ages, causing 18-30 million cases and 5-8 million deaths annually worldwide. However,
      early diagnosis of sepsis is challenging due to the diversity and overlap of symptoms with
      other disorders and the lack of an early and accurate diagnostic method. Hancock and
      colleagues defined a gene expression signature characteristic of biological changes occurring
      during sepsis, known as cellular reprogramming (CR) and reflecting a type of immune amnesia
      (inability to respond to bacterial signals). This signature was shown to predict the
      development of sepsis and organ failure at first clinical presentation in the emergency room,
      by examining patient blood samples taken during an initial pilot single-center study.

      This project will validate and refine the CR signature and demonstrate reproducibility,
      specificity, and sensitivity in a larger multi-center study to enable a new strategy to
      predict Sepsis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of illness</measure>
    <time_frame>24 hours</time_frame>
    <description>Measured by serial Sequential Organ Failure Assessment (SOFA) score monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score monitoring</measure>
    <time_frame>72 hours</time_frame>
    <description>The organs scored are respiratory, cardiovascular, neurologic, hematologic, renal, and liver. Each organ is scored as 0 (best) to 4 (worse) and the total score is the sum of each component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28-day survival rate after admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>Length of stay in the Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Sequential Organ Failure Assessment (SOFA) Score greater than 2</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by serial Sequential Organ Failure Assessment (SOFA) score monitoring</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Suspected Sepsis Group</arm_group_label>
    <description>Participants suspected of potential to develop sepsis recruited at the emergency department.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical Group</arm_group_label>
    <description>Participants undergoing non-emergency scheduled surgery, including ear/nose and throat cases, orthopaedic surgery of the major joints including hip, knee, ankle, shoulder, and wrist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Group</arm_group_label>
    <description>Healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>A blood sample (1 tube) will be collected for the analysis of the CR signature.</description>
    <arm_group_label>Healthy Group</arm_group_label>
    <arm_group_label>Surgical Group</arm_group_label>
    <arm_group_label>Suspected Sepsis Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      RNA samples obtained from whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suspected of sepsis will be recruited at the emergency department of participating
        institutions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Presenting to the Emergency Department

          -  Attending physician suspects possible sepsis based on at least 2 sign of Systemic
             inflammatory response syndrome (SIRS) criteria and suspicion of infection

        Exclusion Criteria:

          -  Patient is terminal (death anticipated in 12 hours)

          -  Informed consent unobtainable if the subject survives to hospital discharge.

          -  Subjects who are unable to provide blood as a standard of care.

          -  Blood sample could not be taken within 24 hours of a physician's first contact with
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E Hancock, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Farmer, BSc</last_name>
    <phone>604-827-5663</phone>
    <email>sfarmer@mail.ubc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas, M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imrana Malik, MD</last_name>
      <phone>713-792-5040</phone>
      <email>imalik@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Rose JD Erfe</last_name>
      <phone>713-792-5040</phone>
      <email>rderfe@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Tang, MD</last_name>
      <email>benjamin.tang@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Benjamin Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hulburt, MD</last_name>
      <email>awphurlburt@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Sweet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Moncaleano Perdomo</name>
      <address>
        <city>Neiva</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Jimenez, MD</last_name>
      <email>caedjimenez@utp.edu.co</email>
    </contact>
    <investigator>
      <last_name>Alvaro Mondragon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hjalmar Bourma, MD</last_name>
      <email>h.r.bouma@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Hjalmar Bourma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, Fjell CD, Boyd JH, Hancock RE. An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation. EBioMedicine. 2014 Nov 1;1(1):64-71.</citation>
    <PMID>25685830</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Bob Hancock</investigator_full_name>
    <investigator_title>Canada Research Chair and Professor, Department of Microbiology and Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The RNA-Seq data will be uploaded to Geo database when the study is complete or upon publication and will be freely available to researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

